Therapeutic | Sacituzumab |
Target | TACSTD2 |
Heavy Chain | QVQLQQSGSELKKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWINTYTGEPTYTDDFKGRFAFSLDTSVSTAYLQISSLKADDTAVYFCARGGFGSSYWYFDVWGQGSLVTVSS |
Light Chain | DIQLTQSPSSLSASVGDRVSITCKASQDVSIAVAWYQQKPGKAPKLLIYSASYRYTGVPDRFSGSGSGTDFTLTISSLQPEDFAVYYCQQHYITPLTFGAGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb ADC |
Isotype | G1 |
Highest Clinical Trial (June '19) | Preregistration |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | IBC Pharmaceuticals, Immunomedics, University of Wisconsin Comprehensive Cancer Center, Yale University |
Conditions Approved | na |
Conditions Active | Breast cancer, Prostate cancer, Solid tumours, Urogenital cancer, Endometrial cancer |
Conditions Discontinued | Pancreatic cancer, Small cell lung cancer |
Notes |